Unmet needs in β-thalassemia and the evolving treatment landscape.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search methodology or original clinical data.
PubMed 38128605 · doi:10.1016/j.tracli.2023.12.003
What was done
This narrative review summarizes standard therapeutic approaches (chronic red blood cell transfusions and iron chelation) for transfusion-dependent and non-transfusion-dependent beta-thalassemia, outlining unmet clinical needs and emerging mechanism-targeted therapies.
What was found
The abstract reports no numerical data, statistics, or study counts. It categorizes novel strategies into three mechanistic classes: correcting alpha/beta globin chain imbalance, targeting ineffective erythropoiesis to reduce transfusion reliance, and managing iron dysregulation, while noting persistent barriers related to blood product availability and treatment adherence.
Why it matters
It outlines how emerging pathophysiological targets may shift management from supportive transfusion care toward disease-modifying regimens in beta-thalassemia.
Limits
As an expert review, it provides no systematic search strategy, risk of bias assessment, or primary empirical data. No quantitative effect sizes, patient outcomes, or safety endpoints are provided in the abstract.
Cited by
- supports Thalassemia is a blood disorder where bone marrow fails to produce adequate red blood cells, necessitating blood transfusions every three to four weeks.